Oxford BioMedica plc (“Oxford BioMedica”, “the Company” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, announced on 4 May 2018 a proposed share capital Consolidation of the existing ordinary share capital of the Company. The effect of the proposed Consolidation will be to reduce the number… Read More
Oxford, UK– 15 February 2018: Oxford BioMedica plc (LSE:Oxford Biomedica) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, today announces that it has completed a major new collaboration & licence agreement with Bioverativ Inc. for the development and manufacturing of lentiviral vectors to treat haemophilia. The… Read More
London, UK – 23 January 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, has announced it that has been awarded a £3 million grant by the UK’s innovation agency, Innovate UK, to support the UK’s efforts to produce viral vectors… Read More
Oxford, UK – 17 January 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, today notes an announcement by Novartis that the supplemental Biologics License Application (sBLA) for Kymriah™ (tisagenlecleucel, formerly CTL019) suspension for intravenous infusion for the treatment of adult… Read More
Oxford, UK – 06 November 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, today notes an announcement by Novartis confirming submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for CTL019 (tisagenlecleucel) for two indications. The application is for the treatment of… Read More
Oxford, UK – 31 October 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, today notes an announcement by Novartis confirming submission of a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for KymriahTM (tisagenlecleucel) suspension… Read More
Oxford, UK – 5 September 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, today announces that John Dawson, Chief Executive Officer, will be presenting at the Rodman & Renshaw Annual Global Investment Conference in New York… Read More